Novo Nordisk Q3 2026: obesity sales up 22% and full-year outlook raised
FROM THE WIRE · FINANCE.YAHOO.COM
This article first appeared on GuruFocus. Adjusted Sales: Increased 4% to DKK 79.2 billion in Q3 2026, driven by volume growth across U.S. and International Operations, primarily in obesity. Adjusted Operating Profit: Increased 27% in Q3 2026, driven by sales growth and a…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishRaised full-year outlook and strong obesity sales growth are relevant for the stock and the pharma sector.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Adjusted sales rose 4% to DKK 79.2 billion in Q3 2026.
- 02Obesity sales grew 22% in the quarter.
- 03The full-year 2026 outlook was raised to DKK 60-70 billion.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets